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Abstract
Introduction: Trichostatin A (TSA) is a well-characterized histone deacetylase (HDAC) inhibitor. TSA modifies the 
balance between HDAC and histone acetyltransferase activities that is important in chromatin remodeling and gene 
expression. Although several previous studies have demonstrated the role of TSA in regulation of estrogen receptor 
alpha (ERα), the precise mechanism by which TSA affects ERα activity remains unclear.
Methods: Transient transfection was performed using the Welfect-EX™Plus procedure. The mRNA expression was 
determined using RT-PCR. Protein expression and interaction were determined by western blotting and 
immunoprecipitation. The transfection of siRNAs was performed using the Oligofectamine™ reagent procedure.
Results: TSA treatment increased acetylation of ERα in a dose-dependent manner. The TSA-induced acetylation of ERα 
was accompanied by an increased stability of ERα protein. Interestingly, TSA also increased the acetylation and the 
stability of p300 protein. Overexpression of p300 induced acetylation and stability of ERα by blocking ubiquitination. 
Knockdown of p300 by RNA interference decreased acetylation as well as the protein level of ERα, indicating that p300 
mediated the TSA-induced stabilization of ERα.
Conclusions: We report that TSA enhanced acetylation as well as the stability of the ERα protein by modulating 
stability of p300. These results may provide the molecular basis for pharmacological functions of HDAC inhibitors in the 
treatment of human breast cancer.
Introduction
Estrogen receptors (ERs) are members of a nuclear hor-
mone receptor superfamily. ERs exist in two isoforms, ERα 
and ERβ, which have highly conserved DNA binding 
domains and ligand binding domains [1,2]. Although these 
receptors display similar binding affinities for 17β-estra-
diol, they have distinct roles in the regulation of gene 
expression and different interactions with unique sets of 
transcriptional factors [2]. Activation of ERα is considered 
a risk factor for the development of breast cancer, since the 
activation leads to cellular proliferation [3,4]. Cumulative 
data from tumor biopsies in the clinic have shown that two-
thirds of breast cancers are ER-positive [5,6]. Tamoxifen, 
which regulates ERα activity, reduces the recurrence and 
death rate of ERα-positive breast cancer [7]. Breast cancer 
patients with expression of ERα are seven to eight times 
more likely to benefit from selective estrogen receptor 
modulators such as tamoxifen than ERα-negative patients 
[5]. ERα expression is therefore considered a significant 
outcome predictor for breast cancer patients to endocrine 
therapy.
The function of ERα is regulated by post-translational mod-
ifications such as phosphorylation [8,9], acetylation 
[10,11], sumoylation [12], and ubiquitination [13]. Among 
these modifications, acetylation is emerging as a central 
process in transcriptional activation of ERα [14]. ERα is 
directly acetylated by p300 at lysine 302 and 303 in the 
absence of ligand, and its acetylation regulates transcrip-
tional activation and ligand sensitivity [10]. ERα is also 
acetylated at lysine 266 and 268 in the presence of coactiva-
tors p160 and p300, which enhances not only DNA binding 
but also transactivation activities. This acetylation was 
reversed by native cellular deacetylases, including trichos-
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tatin A (TSA)-sensitive class I and II histone deacetylases 
(HDACs), and nicotinamide adenine dinucleotide-depen-
dent HDACs (class III, such as Sirt1) [11].
Generally, TSA is known to modify the balance between 
histone acetyltransferase and HDAC activities that induce 
histone hyperacetylation and regulate gene expression. 
Recently, the effect of TSA in acetylation/deacetylation of 
nonhistone proteins has been demonstrated as a diverse reg-
ulatory event, including ubiquitination/proteasomal degra-
dation [15]. TSA effectively represses the mRNA and 
protein level of ERα in the ERα-positive breast cancer cells 
[16,17]. Although several previous studies have demon-
strated the role of TSA-dependent HDACs in regulation 
ERα activity [18-20], the precise mechanism of TSA-
induced activation of ERα remains unclear. We therefore 
explored whether TSA induces acetylation of ERα and 
increases stability of ERα in the present investigation.
Materials and methods
Cell and cell culture
The breast adenocarcinoma cell line T47D (ATCC HB 
8065) and the human cervical carcinoma cell line HeLa 
(ATCC CCL-2) were obtained from the American Type 
Culture Collection (Manassas, VA, USA). Cells were main-
tained in Dulbecco's modified Eagle's medium containing 
10% fetal bovine serum at 37°C in a 5% CO2/95% air incu-
bator.
Plasmids, siRNA and transient transfection
The Myc-tagged ERα, pCMV-Myc-ERα, was constructed 
by inserting a PCR-amplified full-length human ERα frag-
ment into the EcoRI/Sall site of pCMV-Myc. The Myc-
p300 expression vectors were gifted from Dr SC Bae 
(Chungbuk National University, Cheongju, Korea). The 
Myc epitope does not contain the known acetylated lysine 
residues [21,22]. Transient expression of proteins in HeLa 
cells was as described previously [23]. The siRNA 
duplexes targeting p300 and nonspecific siRNA (siGFP) 
were transfected as previously described [24,25].
Western blotting and immunoprecipitation
Western blotting and immunoprecipitation were performed 
as previously described using specific antibodies against 
ERα, p300, Myc (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA), and α-tubulin (Calbiochem, Darmstadt, Ger-
many) [23]. To detect acetylated proteins, 500 μg whole 
cell lysates were incubated with 1 μg anti-pan-acetyl anti-
body (Santa Cruz Biotechnology) or anti-acetylated-lysine 
antibody (Cell Signaling Technology, Danvers, MA, USA), 
precipitated by adding 50 μl protein-A or protein-G agarose 
slurry, and then probed with specific antibodies or normal 
IgG. Acetylation of proteins was confirmed by reciprocal 
immunoprecipitation and western blotting. To detect ubiq-
uitinated proteins, whole cell lysates were immunoprecipi-
tated by 1 μg anti-ubiquitin antibody or anti-Myc antibody 
(Santa Cruz Biotechnology), and were probed using anti-
Myc antibody or anti-ubiquitin antibody, respectively. Rep-
resentative data from at least three independent experiments 
are shown.
Reverse transcriptase-polymerase chain reaction
Total RNA was prepared using the Easy-Blue™ total RNA 
extraction kit (iNtRON Biotechnology, Seongnam, Korea) 
according to the manufacturer's instructions. PCR was per-
formed as described previously using specific primers for 
ERα [26] and p300 [27]. The expression of β-actin was 
monitored as a control.
Results
Trichostatin A enhances acetylation as well as stability of 
ERα protein
Although previous studies have demonstrated that TSA-
dependent HDACs regulated ERα activity, the precise 
mechanism remains unclear. We therefore explored the pos-
sibility that TSA induced acetylation of ERα and thereby 
affected the stability of ERα.
ERα was acetylated in the presence of 1 μM TSA when 
examined using anti-acetylated-lysine antibody in the 
human ERα-positive breast cell line, T47D (Figure 1a). We 
also found that the protein level of ERα was increased in 
the presence of TSA in a dose-dependent manner; the level 
was increased with as low as 0.1 μM TSA (Figure 1b). The 
mRNA level, however, was not altered. This result suggests 
that the TSA-induced ERα may be due to increases in pro-
tein stability, not increases in the transcriptional level.
We next studied the effect of TSA on the acetylation of 
ERα, expression of which is controlled by cytomegalovirus 
promoter using transient transfection of pCMV-ERα in 
HeLa cells. TSA also increased acetylation as well as the 
protein level of ERα in HeLa cells (Figure 1c, d). When 
acetylation was measured with similar amounts of ERα in 
the presence of an inhibitor of proteasome, MG132, the 
increase of acetylation in the presence of TSA was obvious, 
indicating that TSA affected protein stability but not tran-
scription of ERα (Figure 1e). When the stability of ERα 
was measured using cycloheximide, a blocker of de novo 
protein synthesis, we observed that treatment of TSA 
blocked degradation of ERα (Figure 1f).
Trichostatin A increases acetylation and protein stability of 
p300
It has been reported that ERα is directly acetylated by p300 
at the well-conserved lysine residues in the hinge and 
ligand binding domain [10]. p300 acetylates itself, and the 
resulting conformational change modulates its transactiva-
tion potential [28,29].
We therefore investigated whether treatment of TSA 
increased the acetylation of p300 and thereby affected the Kim et al. Breast Cancer Research 2010, 12:R22
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Figure 1 Trichostatin A enhances acetylation as well as stability of ERα protein. (a) T47D cells were treated with or without 1 μM trichostatin A 
(TSA) for 1 hour. Then 500 μg whole-cell lysate was immunoprecipitated (IP) using anti-ERα, anti-acetylated-lysine (Ac-Lys) or normal IgG antibodies, 
and western blot (WB) analyzed by anti-Ac-Lys or anti-ERα antibody as indicated. The expression of ERα and α-tubulin was analyzed by WB as input. 
(b) The ERα-positive T47D cells were treated with the indicated concentrations of TSA for 3 hours. The protein and mRNA expression of ERα were an-
alyzed by WB and RT-PCR, respectively. (c) HeLa cells were transiently transfected with 4 μg Myc-ERα and then treated with or without 1 μM TSA for 
3 hours. Then 500 μg whole-cell lysate was immunoprecipitated using anti-pan-Ac, anti-Ac-Lys or normal IgG antibodies, and probed by anti-Myc 
antibody. The expression of ERα was analyzed by WB using anti-Myc or anti-ERα antibodies as input. (d) HeLa cells were transiently transfected with 
4 μg Myc-ERα and then treated with various concentrations of TSA for 3 hours. Then 500 μg whole-cell lysate was immunoprecipitated using anti-
pan-Ac antibody, and probed by anti-Myc antibody. The expression of ERα was analyzed by WB using anti-Myc or anti-ERα antibodies as input. (e) 
HeLa cells were transiently transfected with 4 μg Myc-ERα and then treated with 1 μM TSA for 3 hours and 10 μM MG132 for 2 hours as indicated. Then 
1 mg whole-cell lysate was immunoprecipitated using anti-Lys-Ac antibody, and probed by anti-Myc antibody. The expression of ERα was analyzed 
by WB using anti-Myc antibodies as input. (f) T47D cells were treated with or without 1 μM TSA for 3 hours in the presence of 10 μM cycloheximide 
(CHX) for the indicated time periods. At the end of treatment, whole-cell lysates were prepared and the expression of proteins was analyzed by WB. 
Density of the ERα protein band was determined using an image analysis system. The values were normalized to that of α-tubulin and expressed as 
a percentage of CHX-untreated control. Each data point represents the mean ± standard error of the mean of at least three independent experiments. 
**P < 0.01, -TSA vs. +TSA.
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acetylation level of ERα. As expected, acetylation of p300 
was increased in the presence of TSA in T47D cells (Figure 
2a). This observation suggests that the TSA-dependent 
HDACs are associated with deacetylation of p300. Similar 
to ERα, the protein level of p300 was significantly 
increased in the presence of TSA in a dose-dependent and 
time-dependent manner; however, the mRNA level of p300 
was not altered (Figure 2b). Similar results were observed 
in p300 proteins overexpressed in HeLa cells (Figure 2c, d). 
The increase in acetylation of p300 was clearly observed in 
the presence of TSA when degradation of p300 was 
blocked by an inhibitor of proteasome, MG132 (Figure 2e). 
This result indicates that TSA affected protein stability 
rather than transcription of p300. The protein level of p300 
was maintained by TSA in the presence of cycloheximide, 
indicating that TSA increases the protein stability of p300 
(Figure 2f).
p300 enhances the acetylation and stability of ERα protein
We then examined whether p300 increased acetylation and 
stability of the ERα protein. When p300 was exogenously 
introduced together with ERα in HeLa cells, acetylation as 
well as the protein level of ERα were largely increased 
(Figure 3a). The increase in ERα depended on the amount 
of p300 expressed (Figure 3b). We also found that ERα was 
physically associated with p300 in the presence of TSA by 
co-immunoprecipitation assays (Figure 3c).
The protein level of ERα was maintained in the presence of 
p300 while it largely decreased in the absence of p300, 
when cells were treated with cycloheximide for 3 hours 
(Figure 4a). Ubiquitination of ERα was dramatically 
repressed in the presence of p300. These results indicate 
that p300-induced acetylation of ERα is associated with 
blocking proteasomal degradation of ERα (Figure 4b).
Finally, we confirmed the role of p300 in TSA-induced 
ERα protein stability after knockdown of p300 using RNA 
interference. As shown in Figure 5, the TSA-induced acety-
lation and the increase in the protein level of ERα were 
largely diminished when expression of p300 was repressed, 
in both T47D and HeLa cells.
Together, these results demonstrated that TSA increased the 
stability of ERα protein by enhancing acetylation and stabi-
lization of p300.
Discussion
TSA not only inhibits growth of ERα-positive breast cancer 
cells in vitro but also inhibits breast tumor growth in vivo 
[16,17,30]. TSA may exert these beneficial effects against 
tumor growth by blocking deacetylation of histones and 
transcriptional factors, which subsequently alters transcrip-
tional activity of target genes [15,31]. Here we report that 
TSA induces stability of ERα protein by enhancing acetyla-
tion and stability of p300, which may contribute to pharma-
cological effects of TSA.
Previous studies demonstrated that ERα is acetylated at 
multiple lysine residues, which may have different func-
tions in the regulation of ERα activity. ERα was acetylated 
at lysine 266 and 268 in the presence of ligand in a steroid 
receptor coactivator-dependent manner [11]. ERα was also 
acetylated at lysine 302 and 303 in the presence of p300, 
and thereby regulated transcriptional activation and ligand 
sensitivity of ERα [10]. Ubiquitination at the same lysine 
residues was shown to regulate degradation of ERα [13]. 
The TSA-induced acetylation of ERα was accompanied 
with increased protein level of ERα (Figure 1), and p300 
protected ubiquitination of ERα in our investigation (Figure 
4b) - supporting the hypothesis that acetylation of ERα, 
probably at lysine 302 and 303 residues, is important for 
maintaining protein stability.
This observation is similar to the p300-induced acetylation 
of p53 or that of Smad7, which blocks ubiquitination and 
degradation of the protein [32,33]. Other nuclear receptors 
such as LXRα and AR are also present as acetylated forms 
that are involved in transactivation and other post-transla-
tional modifications such as ubiquitination [34,35]. Our 
finding contrasts, however, with previous reports that TSA 
downregulated the protein and mRNA level of ERα in ERα-
positive breast cancer cells [16,17]. When MCF7 or T47D 
cells were treated with TSA for a prolonged period, we also 
observed a similar downregulation of ERα, indicating that 
TSA may affect ERα activity through at least two different 
mechanisms: transcriptional repression of the ERα pro-
moter, and protein stability of ERα at the post-translational 
level. TSA may accomplish its beneficial effects against 
breast cancer by inducing sequential and/or divergent modi-
fications of ERα at different regulation levels.
p300 was originally identified as E1A, which is a transcrip-
tional co-activator for various transcription factors, includ-
ing ERα [36]. The intrinsic histone acetyltransferase 
activity of p300 catalyzes acetylation of histone, which 
induces chromatin remodeling and subsequent transcrip-
tional activation of target genes. p300 also acetylates non-
histone proteins such as p53 and Smad7, which leads to 
stabilization of target proteins [33,37]. Interestingly, the 
histone acetyltransferase domain of p300 acetylates itself 
[28]. Blanco-García and colleagues demonstrated recently 
that PCAF was acetylated by itself and by p300. Deacetyla-
tion of PCAF was catalyzed mainly by HDAC3, which 
affected subcellular localization of PCAF [38]. In the case 
of p300, acetylation was shown to increase transactivation 
activity and protein-protein interactions [28,29].
In the present study, we found another role for acetylation 
of p300 in the stabilization of p300 protein itself. Stabiliza-
tion of p300 is induced within 3 hours of TSA treatment, 
which is similar to the TSA-induced acetylation and stabili-
zation of ERα (Figure 2). Our finding, however, contradicts 
previous observations that autoacetylation of p300 did not 
alter its stability [29]. We believe this conflict may be due Kim et al. Breast Cancer Research 2010, 12:R22
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Figure 2 Trichostatin A increases acetylation and protein stability of p300. (a) T47D cells were treated with or without 1 μM trichostatin A (TSA) 
for 1 hour. Then 500 μg whole-cell lysate was immunoprecipitated (IP) using anti-p300 or anti-lysine antibody, and western blot (WB) analyzed by anti-
p300 or anti-lysine antibody, respectively. The expression of p300 or anti-ERα was analyzed by WB using anti-p300 or anti-ERα antibodies as input. (b) 
T47D cells were treated with the indicated concentrations of TSA for 3 hours (upper) treated with 1 μM TSA for indicated period (lower). The protein 
and mRNA expression of p300 was analyzed by WB and RT-PCR, respectively. (c) HeLa cells transiently transfected with 4 μg Myc-ERα were treated 
with or without 1 μM TSA for 3 hours. Then 500 μg whole-cell lysate was immunoprecipitated using anti-acetylated-lysine (Ac-Lys) or normal IgG an-
tibodies, and then probed by anti-p300 antibody. The expression of p300 and ERα was analyzed by WB using anti-p300 and anti-ERα antibodies as 
input. (d) HeLa cells were transiently transfected with 4 μg Myc-ERα and treated with various concentrations of TSA for 3 hours. Then 500 μg whole-
cell lysate was immunoprecipitated using anti-Ac-Lys antibody, and probed by anti-p300 antibody. The expression of p300 was analyzed by WB using 
anti-p300 antibodies as input. (e) HeLa cells were transiently transfected with 4 μg Myc-ERα and then treated with 1 μM TSA for 3 hours and 10 μM 
MG132 for 2 hours as indicated. Then 1 mg whole-cell lysate was immunoprecipitated using anti-Ac-Lys antibody, and probed by p300 antibody. The 
expression of p300 was analyzed by WB as input. (f) T47D cells were treated with or without 1 μM TSA for 3 hours in the presence of 10 μM cyclohex-
imide (CHX) for the indicated time periods. At the end of treatment, whole-cell lysates were prepared and the expression of proteins analyzed by WB. 
The density of p300 protein band was determined using an image analysis system. The values were normalized to that of α-tubulin and expressed as 
a percentage of CHX-untreated control. Each data point represents the mean ± standard error of the mean of at least three independent experiments. 
**P < 0.01, -TSA vs. +TSA.
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to different experimental conditions such as the expression 
level of p300 and the cell lines examined. Since p300 medi-
ates acetylation of many proteins including histone and 
ERα, acetylation and subsequent stabilization of p300 may 
regulate the pharmacological effects of TSA through acti-
vation of diverse cellular transcription factors in breast can-
cer cells.
Our results together with those of other studies strongly 
suggest that the TSA-dependent HDACs are involved in 
acetylation of ERα [18-20]. The TSA-sensitive HDACs are 
class I and class II, which form a multiprotein repressor 
complex to remove the acetyl group from lysine residues of 
histones [39]. Indeed, HDAC1 and HDAC4, which belong 
to class I and class II, respectively, interacted with ERα and 
suppressed the transcriptional activity and expression of 
ERα [18,19]. On the contrary, nicotinamide adenine dinu-
cleotide-dependent HDACs such as Sirt1 have been demon-
strated to deacetylate ERα, probably at lysine 266 and 268, 
which enhanced the DNA binding and transactivation of 
ERα [11,40]. It would be interesting to know the unique 
function of each HDAC subtype as well as of each lysine 
residue in the regulation of ERα activity, such as protein 
stability and transactivation function. Especially, resvera-
trol - a Sirt1 activator - caused inhibition of estrogen-depen-
Figure 3 p300 regulates acetylation and the protein level of ERα. 
(a) HeLa cells were transiently transfected with 2 μg Myc-ERα with or 
without 2 μg Myc-p300. Then 500 μg whole-cell lysate was immuno-
precipitated (IP) using anti-acetylated-lysine (Ac-Lys) or normal IgG an-
tibodies, and probed by anti-ERα antibody. The expression of proteins 
was analyzed by western blot (WB) using anti-Myc or anti-ERα anti-
body as input. (b) HeLa cells were transiently transfected with 2 μg 
Myc-ERα or the indicated amounts of Myc-p300 or empty vector. The 
expression of proteins was analyzed by WB using anti-ERα, anti-Myc or 
anti-p300 antibodies. (c) HeLa cells were transiently transfected with 4 
μg Myc-ERα and treated with or without 1 μM trichostatin A (TSA) for 3 
hours. Then 500 μg whole-cell lysate was immunoprecipitated using 
anti-p300 or normal IgG antibodies, and probed by anti-Myc antibody.
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dent cell proliferation, further supporting the notion that 
modifying ERα acetylation strongly influences epithelial 
cell growth in breast tissue [41]. Further molecular details 
of the acetylation of ERα and the resulting estrogen signal-
ing could contribute to a novel therapeutic strategy against 
breast cancer.
Conclusions
Several previous studies have demonstrated the role of TSA 
in regulation of ERα, but the precise mechanism of how 
TSA affects ERα activity remains unclear. We report that 
TSA enhanced acetylation as well as the stability of the 
ERα protein by modulating the stability of p300. Our 
results may provide the molecular basis concerning phar-
macological functions of histone deacetylase inhibitors 
against human breast cancer.
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anti-ERα antibody. The expression of p300 and ERα was analyzed by 
western blot (WB) using anti-p300 or anti-Myc as input.
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